Home › Multiple Myeloma › Missouri › St. Louis
Multiple Myeloma clinical trials in St. Louis, MO
24 studies for Multiple Myeloma are looking for participants at sites in and around St. Louis (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relapsed/Refractory Multiple Myeloma
RecruitingPhase 2
- Washington University School Of Medicine, St Louis
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
RecruitingPhase 1/2
- Washington University School of Medicine, St Louis
A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma (DURGA-2)
RecruitingPhase 1
- Research Site, St Louis
A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
RecruitingPhase 2
- Washington University School Of Medicine, St Louis
A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
RecruitingPhase 4
- Washington University School Of Medicine, St Louis
Collection of Tissue Samples for Cancer Research
RecruitingObservational study
- Washington University - St. Louis, St Louis
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
RecruitingPhase 2
- Washington University School of Medicine, St Louis
A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma
RecruitingPhase 3
- Washington University School of Medicine, St Louis
A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma
RecruitingPhase 1/2
- Research Site, St Louis
A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)
RecruitingPhase 2
- GSK Investigational Site, Bridgeton · 15 mi away
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
RecruitingPhase 3
- Mercy Infusion Center - Chippewa, St Louis
- Mercy Hospital South, St Louis
- Missouri Baptist Medical Center, St Louis
- and 4 more
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
RecruitingPhase 3
- Research Site, St Louis
Measurable Residual Disease-Guided Post-Transplant Elranatamab Maintenance
RecruitingPhase 2
- Washington University School of Medicine, St Louis
A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
RecruitingPhase 2
- Washington University/Siteman Cancer Center, St Louis
Recombinant Human IL-7 (NT-I7) in Relapsed/Refractory Multiple Myeloma Following BCMA CAR-T Therapy (Cilta-cel)
RecruitingPhase 1
- Washington University School of Medicine, St Louis
Washington University Participant Engagement and Cancer Genomic Sequencing Center (WU-PE-CGS)
Recruiting
- Washington University School of Medicine, St Louis
Safety and Efficacy of CS1 CAR-T (WS-CART-CS1) in Subjects With Multiple Myeloma
RecruitingPhase 1
- Washington University School of Medicine, St Louis
64Cu-LLP2A for Imaging Hematologic Malignancies
RecruitingEarly phase 1Healthy volunteers welcome
- Washington University School of Medicine, St Louis
Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
RecruitingPhase 3
- Saint Louis Cancer and Breast Institute-South City, St Louis
- Mercy Hospital South, St Louis
- Missouri Baptist Medical Center, St Louis
- and 5 more
Selinexor Maintenance Post CAR-T Cell Therapy for Multiple Myeloma
RecruitingPhase 1
- Washington University School of Medicine, St Louis
An AI-Generated, Personalized Question Prompt List Intervention for Patients With Hematologic Cancers
Recruiting
- Washington University School of Medicine, St Louis
Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma
RecruitingPhase 1
- Washington University /ID# 266972, St Louis
Post-Op Pain Control for Prophylactic Intramedullary Nailing.
RecruitingPhase 3
- Saint Louis University, St Louis
Lymphodepleting Total Body Irradiation (TBI) Plus Cyclophosphamide Prior to Ciltacabtagene Autoleucel (Carvykti; Cilta-cel) for Multiple Myeloma (MM) Patients With Impaired Renal Function
RecruitingPhase 1
- Washington University School of Medicine, St Louis
About Multiple Myeloma
Multiple myeloma is a cancer that begins in plasma cells, a type of white blood cell. Discover symptoms, diagnostic tests, and treatments for myeloma.
More about Multiple Myeloma on MedlinePlus
Multiple Myeloma trials in other cities
- New York City, NY60 studies
- Boston, MA42 studies
- Atlanta, GA41 studies
- Houston, TX38 studies
- Durham, NC37 studies
- Nashville, TN32 studies
- Denver, CO27 studies
- Rochester, MN24 studies
- Columbus, OH24 studies
- Baldwin Park, CA23 studies
- Chicago, IL22 studies
- Seattle, WA22 studies
Other studies in St. Louis
- Non-Small Cell Lung Cancer73 studies
- Breast Cancer64 studies
- Metastatic Cancer54 studies
- Colorectal Cancer50 studies
- Prostate Cancer46 studies
- Cancer (all types)46 studies
- Lung Cancer39 studies
- Ovarian Cancer38 studies
- Pancreatic Cancer33 studies
- Endometrial Cancer29 studies
- Head and Neck Squamous Cell Carcinoma28 studies
- Heart Failure26 studies
From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.